Oncoinvent, Announces

Oncoinvent Announces First Patient Dosed in its Phase 2 Clinical Trial of Radspherin® in Ovarian Cancer Patients

Veröffentlicht: 07.08.2025 um 18:07 Uhr, prnewswire.co.uk

Oncoinvent AS Norway

View original content:https://www.prnewswire.co.uk/news-releases/oncoinvent-announces-first-patient-dosed-in-its-phase-2-clinical-trial-of-radspherin-in-ovarian-cancer-patients-302272777.html

en | boerse | 67940733 |